^
Association details:
| Biomarker: | KAT6A-CREBBP fusion + FLT3-TKD mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | cytarabine (DNA synthesis inhibitor, DNA-directed DNAP inhibitor) + Rydapt (midostaurin) (Multi-tyrosine kinase inhibitor) + daunorubicin (Topoisomerase II inhibitor, DNA intercalator) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
De Novo M5b AML With t(8;16) (p11.2; p13.3) KAT6A/CREBBP Fusion and FLT3-TKD Mutation: Analysis of Mitelman Database
Published date:
09/21/2022
Excerpt:
We present a case of AML...The translocation results in KAT6A/CREBBP fusion….The patient was started on a 7+3 induction regimen with cytarabine and daunorubicin. Midostaurin was added due to FLT3-TKD mutation. She was found to be disease free on a follow-up marrow biopsy...
